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Abstract
Farnesylation is an important post-translational modification catalyzed by farnesyltransferase (FTase). Until recently it was
believed that a C-terminal CaaX motif is required for farnesylation, but recent experiments have revealed larger substrate
diversity. In this study, we propose a general structural modeling scheme to account for peptide binding specificity and
recapitulate the experimentally derived selectivity profile of FTase in vitro. In addition to highly accurate recovery of known
FTase targets, we also identify a range of novel potential targets in the human genome, including a new substrate class with
an acidic C-terminal residue (CxxD/E). In vitro experiments verified farnesylation of 26/29 tested peptides, including both
novel human targets, as well as peptides predicted to tightly bind FTase. This study extends the putative range of biological
farnesylation substrates. Moreover, it suggests that the ability of a peptide to bind FTase is a main determinant for the
farnesylation reaction. Finally, simple adaptation of our approach can contribute to more accurate and complete elucidation
of peptide-mediated interactions and modifications in the cell.
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Introduction
Protein prenylation is a post-translational modification in which
a prenyl group (farnesyl or geranylgeranyl) is attached to the
protein via a thioether bond to a cysteine at or near the carboxy
terminus of the protein (reviewed in [1,2]). Protein farnesyltrans-
ferase (FTase) and geranylgeranyltransferase type I (GGTase-I) are
also called CaaX prenyltransferases, due to their ability to catalyze
modification of peptides and substrate proteins bearing the
carboxy terminal (C’) Cys-aliphatic-aliphatic-variable amino acid
(Ca1a2X) motif [3].
Upon binding of the substrate and the C-terminal Ca1a2X
motif, the catalytic zinc ion of FTase coordinates the thiol side
chain of the cysteine and catalyzes the covalent attachment of the
lipid anchor to this residue. A detailed view of this mechanism has
been obtained by a series of structures solved at different stages of
the reaction [4]. After the covalent attachment of the isoprenoid in
the cytoplasm, substrate proteins can undergo further processing,
resulting in a C’ structure that is able to serve as a specific
recognition motif in certain protein-protein interactions [5] and to
direct the modified protein towards incorporation into cellular
membranes [6].
A wide range of proteins involved in diverse cellular functions
require this post-translational modification for their action [2].
While numerous proteins have been experimentally shown to
undergo farnesylation in vivo [7,8,9], it is likely that many FTase
substrates remain to be discovered. There is a wide interest in
the mapping of FTase targets in the genome, in part due to
the therapeutic potential of FTase inhibitors against cancer
[10,11,12], as well as parasitic infection [13,14]. Identification of
new targets might lead to novel therapeutic approaches [15].
Moreover, the elucidation of cellular FTase targets might shed
light on the function of various proteins, as well as on the cellular
network of interactions.
Computational approaches have predicted FTase targets based
on sequence features of known targets [7,8]. These methods show
good performance in terms of sensitivity, i.e. known targets are
correctly identified. Thus, prenylation is mainly defined by the last
four residues of the protein, although additional weaker sequence
constraints have also been identified upstream in the sequence
[16]. Other approaches were based on manual inspection and
derived from structural features [9].
Substrate specificity has also been examined using peptide
libraries. A comprehensive study by Hougland et al. on the
farnesylation of a large synthetic peptide library has allowed a
detailed characterization of FTase specificity [17]. In addition to
compiling a large and clean dataset of peptides that contains both
efficient substrates and non-substrates for FTase, this study
discovered a third group of sequences that are farnesylated only
under single-turnover (STO) conditions ([E].[S]). Analysis of
peptide substrates has also demonstrated that reactivity depends
on synergy between the side chains at the a2 and X positions [18].
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complex than the simple Ca1a2X motif model, and that non-
canonical sequences can serve as substrates.
A large number of structures have been determined for FTase
and FTase-substrate peptide complexes [19]. The peptide binding
pocket is well-characterized, although a structure of the ternary
FTaseNfarnesyl diphosphate(FPP)Npeptide in an active conforma-
tion has not been determined [9]. The Ca1a2X cysteine sulfur
atom (prior to the product formation) coordinates the catalytic
Zn
2+ ion together with side chains (D297, C299 and H362) of the
FTase b-subunit. The a1 side chain points out of the binding
pocket and faces the solvent, while the a2 side chain is buried
within the binding pocket and interacts both with the farnesyl
chain of FPP and the residues lining the pocket. The C’ X position
interacts with residues mostly from the FTase b-subunit and is
considered the main determinant for the specificity between FTase
and GGTase-I 9. Finally, two highly conserved hydrogen bonds
are formed: 1) between the C-terminal carboxylate group and the
side chain of FTase Q167a and 2) between the a2 backbone
carbonyl oxygen and the side chain of FTase R202b (Figure 1).
Despite this detailed structural information, only a handful of
different peptide sequences have been solved in complex with
FTase.
We previously developed a scheme for modeling the structures
of peptide-protein complexes (Rosetta FlexPepDock [20]), which is
incorporated within the Rosetta modeling suite framework [21].
This protocol is the starting point for the development of a
structure-based scheme for the prediction of peptide binding
specificity (FlexPepBind). Specifically, to refine FlexPepBind for
the prediction of FTase binding peptides, we have incorporated
constraints derived from the conserved features in solved FTase
structures and adapted the energy function to distinguish between
reacting and non-reacting tetrapeptides (based on an underlying
assumption that tetrapeptides that bind will react, while those that
do not bind will not react). We trained and tested this protocol
against the recent dataset published by Hougland et al. [17].
Validation of the protocol against several independent sets showed
accurate prediction of peptides that could be farnesylated, both
under multiple turnover (MTO) and single turnover (STO)
conditions. Evaluation of all possible Cxxx peptides identified a
previously uncharacterized class of farnesylation targets that
contain an acidic C-terminal residue. The 13 peptides predicted
to bind with best affinity were experimentally shown to indeed
undergo farnesylation in vitro. Finally, a genomic scan for novel
FTase targets revealed 77 novel putative FTase targets previously
undetected by sequence-based approaches. Among these, 13 out of
16 selected novel putative farnesylation targets were indeed
farnesylated by FTase in an in vitro experimental validation.
FTase-peptide binding is a model system for our approach to
peptide-protein binding specificity prediction and design. Our
protocol can easily be adapted to additional peptide-protein
interactions where both experimental structure and affinity data
are available, thereby providing a mechanism to identify targets
not detectable by sequence conservation only.
Results
FlexPepBind discrimination of FTase binding and non-
binding peptides
Recently Hougland et al. performed a large-scale study, in which
they characterized a TKCxxx peptide library for reactivity with
rat protein farnesyltransferase (rat FTase) [17]. Out of an ini-
tial library of 213 sequences, 77 peptides are farnesylated under
multiple turnover (MTO) conditions, and 51 sequences are not
farnesylated under any conditions. Interestingly, the remaining 85
sequences are farnesylated under single turnover (STO) conditions
but not under MTO conditions.
We set out to use FlexPepBind and the structural data available
for FTase to discriminate MTO sequences from non-reactive
(NON) peptide sequences, using the 77 MTO and 51 NON
peptide sequences as our training set (128 peptides in total; Dataset
S1A). Towards this end, we used the high resolution structure of
human FTase in complex with a peptide derived from the carboxy
terminus of Rap2a and a farnesyl diphosphate (FPP) analog (PDB:
1tn6 [9]) to create a starting model. The bound peptide was
truncated to include only the terminal Ca1a2X motif. Different
peptide sequences were then threaded onto the peptide backbone
and used as starting structures.
Initially, we modeled peptide-FTase complex structures for
different peptide sequences by applying the Rosetta FlexPepDock
protocol to the threaded starting models. This protocol was
developed previously in our lab for the modeling and refinement
of peptide-protein complex structures to high resolution [20]. Our
simulations included three constraints, namely the conservation of
the 2 structurally conserved hydrogen bonds (C’ carboxylate -
FTase Q167a;a 2 backbone carbonyl oxygen - FTase R202b) and
the location of the cysteine sulfur atom coordinating the Zn
2+ ion
(Figure 1, see Methods for more details).
For each simulation, the energy of the best scoring Cxxx peptide
was extracted (see Methods for further details). Figure 2A shows
the Receiver Operating Characteristic (ROC) plot for the ability of
the peptide energy to discriminate between MTO sequences and
non-substrate sequences. The plot shows very good discrimination
with an Area Under the ROC Curve (AUC) value of 0.915 on our
training set.
These results demonstrate that a structure-based evaluation of
the peptide energy can distinguish very well between farnesylated
and non-farnesylated peptide sequences. Since the known
constraints restrict the simulation to a closely defined region in
the binding site, we reasoned that a simpler and faster protocol
Author Summary
Linear sequence motifs serve as recognition sites for
protein-protein interactions as well as for post-translation-
al modifications. One such motif is the CaaX box located at
protein C-termini that serves as prenylation site. This
prenylation is critical for many signal transduction related
proteins and it is thus an important goal to uncover the
range of prenylated proteins. Due to poor generalization
ability, sequence based computational methods can only
go so far in predicting novel targets. In this study, we
introduce a novel structure based modeling approach that
allows both recovery of known farnesylation substrates, as
well as detection of a new class of farnesylation targets.
We demonstrate high accuracy in retrospective discrimi-
nation between substrates and non-substrates of farnesyl-
transferase (FTase). More importantly, in a prospective
study, in vitro experiments validate that 26/29 predicted
peptides indeed undergo farnesylation. These novel
peptides were derived either from actual human proteins,
or predicted to bind particularly well to FTase. Other than
the discovery of putative novel farnesylation targets in the
human genome, as well as possible inhibitors, we provide
insights into the main determinants of farnesylation. Our
approach could be easily extended to additional peptide-
protein interactions and help the elucidation of the cellular
peptide-protein interaction network.
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simplified protocol therefore includes only a minimization using
the Rosetta energy function [21,22] under constraints to retain the
2 structurally conserved hydrogen bonds and the cysteine sulfur
atom location coordinating the Zn
2+ ion (see above and Methods
for more details). This protocol yielded similar results with an
AUC value of 0.875 on the training set. A peptide energy
threshold of -0.4 (i.e. sequences with energy below/above -0.4 are
predicted to be binders/non-binders and therefore farnesylated/
non-farnesylated, respectively) corresponds to a 69% True Positive
Rate (TPR) and 8% False Positive Rate (FPR). A more stringent
threshold of -1.1 energy units corresponds to a 44% TPR and 2%
FPR (Figure 2A). With the two protocols exhibiting similar
performance, we decided to proceed further using the fast
minimization protocol. (Performance on the training set using
additional sampling and scoring schemes is summarized in Table
S1.)
Validation of FlexPepBind on independent test sets
To assess FlexPepBind using the selected thresholds, we evaluated
performance on three independent test sets (Dataset S1B-D online).
1. Secondary synthetic library (Dataset S1B). In their
original paper, Hougland et al. [17] assayed the activity of a
secondary synthetic peptide library, biased towards sequences
containing canonical amino acids at the a2 and X positions. In this
library, 29 peptides displayed MTO activity with FTase and 15
peptides were not reactive. The sequences from this library were
not used at any stage during the development of our protocol. The
ROC plot for this test set in Figure 2A shows an AUC value of
0.913 that is even better than for the training set. Applying the
thresholds identified in the training set yields 86% TPR/12.5%
FPR for the 20.4 threshold, and 72%/12.5% for the 21.1
threshold, respectively.
2. Known FTase substrate sequences (Dataset S1C). This
dataset is based on Table S1 from the study by Hougland et al. [17]
which lists the carboxy terminal sequences of known proteins that
serve as substrates for FTase, collectedfromdifferent studies [7,8,9].
Figure 2B shows the energy distribution of the known sequences, as
estimated by FlexPepBind. Applying the thresholds obtained from
the training set, we are able to recover 64% of the known substrates
with the stringent threshold, and 85% of the known substrates with
the less restrictive criterion. These values are much better than the
TPR obtained for the training set.
3. Ca1a2L library (Dataset S1D). In a recent work by
Krzysiak et al. [23], a synthetic library of peptides of the form
Ca1a2L, ‘‘canonical’’ GGTase-I substrates, was characterized for
reactivity with FTase. In this study, sequences for which product
conversion was detected by HPLC were labeled as ‘true’ substrates,
while sequences for which no conversion was detected were labeled
as ‘false’ substrates [23]. Using the threshold of -0.4 results in
Figure 1. Structural overview of the FTase binding pocket. A top view of the binding pocket of human FTase (orange) in complex with C’
CNIQ peptide in Rap2a (green), and a farnesyl analog (red) (PDB: 1tn6 [9]). Arrows indicate the constraints used during the simulations: the two
structurally conserved hydrogen bonds (C’ carboxylate to FTase Q167a and the a2 backbone carbonyl oxygen to FTase R202b), as well as the sulfur-
Zn
2+ coordination. The figure was created using PyMOL (http://www.pymol.org).
doi:10.1371/journal.pcbi.1002170.g001
Identification of Novel FTase Targets
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performance on other peptide libraries (Figure 2C). These results
demonstrate that the C’ residue is not necessarily the main
determinant of FTase substrate selectivity.
Exploration of the full substrate sequence space
Using FlexPepBind, we modeled all of the 8000 possible Cxxx
sequences and scored them according to our protocol. The
thresholds for the discrimination of MTO/NON predict that 1349
(17%; stringent threshold=21.1) and 2309 (29%; thresh-
old=20.4) of all tetramer peptide sequences could be possible
substrates (see Figure 3). This set of putative farnesylation targets
suggest a much more versatile binding motif than previously
accepted (see Figure 4): while position a2 of the Ca1a2X motif is
still prominently aliphatic (ILE/VAL/LEU/PHE), positions a1
and X are less restricted than previously reported (compare
Figure 4C to Figures 4A&B). In particular, we identify within this
set a novel class of farnesylation targets that contain an acidic
residue at the C-terminus (238/1349 putative targets; ,20%; see
Figure 4D).
Figure 4C indicates that the minimization-based protocol tends
to miss larger residues at the C-terminal X position. Indeed,
assessment of the prediction accuracy for this position on the
training set shows that only 1/8 CxxF and 0/3 CxxW sequences
are correctly predicted with the chosen protocol (CxxM peptides
are predicted with higher accuracy: 10/14). Using the FlexPep-
Dock based protocol, performance increases to: 6/8 CxxF; 2/3
CxxW and 11/14 CxxM, demonstrating that CxxF peptides are
indeed rescued by the additional backbone flexibility. Therefore, it
might be advisable to use the FlexPepDock based protocol for
peptides that contain a bulky C-terminal side chain.
Comparison to sequence-based approaches
We compared our predictions to the PrePS [7] prediction of
prenylation targets on the initial training set of peptides. Re-
garding the discrimination of MTO substrates from non-active
peptides, PrePS results are comparable to FlexPepBind (AUC of
0.92, with a threshold corresponding to 60% TPR for 2% FPR).
However, the performance for STO peptides is significantly better
for our structure-based approach: while FlexPepBind recovers
47% and 32% of the STOs with the loose and stringent thresholds
concordantly, PrePS predicts only 14% of these sequences as
substrates.
Experimental confirmation of novel substrate class
Since our retrospective studies indicated that our approach can
very accurately retrieve actual farnesylation targets, we were
interested in testing it prospectively – could novel targets be indeed
identified? We selected the 13 best scoring peptides (i.e. predicted
tightest binders), yet previously uncharacterized for experimental
validation. These are mostly ‘non-canonical’ peptides, including 5
peptides with an acidic C-terminal residue. Indeed, PrePS [7]
predicts only 2 out of the top-scorers to be FTase substrates. In vitro
Figure 2. FlexPepBind allows good discrimination between substrate - and non-substrate sequences. A. ROC-plot of the discrimination
between MTO peptide sequences and non-active peptide sequences on the training set with the FlexPepDock based protocol (green), the fast,
minimization based protocol (red), an independent test set (blue), and expected random discrimination (black). The Area Under the ROC Curve (AUC)
value for the training set is 0.915/0.875 for the FlexPepDock and minimization based protocols, accordingly. Note that the performance of the
minimization-based protocol on the test set is even better than on the training set (0.91 vs. 0.875). For the indicated points on the plot, an energy
threshold of -0.4 corresponds to a 69% True Positive Rate (TPR) and 8% False Positive Rate (FPR). A more stringent threshold of -1.1 energy units
corresponds to a 44% TPR and 2% FPR. Training and test sets are detailed in Dataset S1A&B. B+C. Validation on additional independent test
sets shows robust and reliable performance of our modeling protocol. B. The distribution of energies for known FTase substrate sequences.
The horizontal line indicates the -0.4 threshold obtained from the training set (see Text). Using this criterion, 85% of the known binders are recovered.
Note that this corresponds to a significantly better TPR than the one obtained on the training set. C. Energy distribution for a synthetic library of
Ca1a2L peptides investigated in Krzysiak et al. [23]. As in B., the horizontal line indicates a threshold of -0.4, which in this case displays 87.5% TP and
12.5% FP rates (i.e., only 3 false negatives and 2 false positives). The peptide sequences and scores can be found in Dataset S1C&D.
doi:10.1371/journal.pcbi.1002170.g002
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undergo farnesylation catalyzed by FTase: 10 under MTO
conditions and 3 under STO conditions (Table 1A). These results
demonstrate the robustness of our protocol and its exceptional
accuracy. Importantly, they confirm the novel class of farnesyla-
tion substrates that contain a negatively charged C-terminal
residue (Figure 4D).
Structural investigation of this novel class of substrates suggests
that the negatively charged C’ side-chain is stabilized by FTase
residue His 149bwhile accepting a hydrogen bond from Trp102b
(GLU) and creating an additional hydrogen bond with the side-
chain of Ser99b (GLU & ASP) (see Figure S1). Additional polar
interactions with water molecules are possible but were not
explicitly modeled.
Genomic scan for novel human FTase targets
Equipped with a score that can predict both known and novel
FTase targets, we set out to scan the human genome for proteins
that may undergo farnesylation. Our protocol was developed based
on experimental assays on rat FTase (and the structure of human
FTase [9]). Since rat and human FTases show very high sequence
identity (92% and 96% for subunits a and b respectively), and none
of the sequence differences are located at or near the peptide
binding site, we are confident that our prediction scheme can be
applied to human farnesylation as well.
We identified 756 unique proteins in human SwissProt [24] that
contain the Cxxx motif at their carboxy terminus. 167 and 309 of
these protein sequences obtained scores lower than the 21.1 and
20.4 threshold values, respectively, indicating that these proteins
might be farnesylated by FTase. We focused on the group of 167
proteins detected with the more stringent threshold.
Could these proteins indeed be FTase substrates? Several
indications support our predictions: First, amongst the 167
candidates, 42 contain a Cxxx motif of a known FTase substrate.
Secondly, the Gene Ontology (GO) [25] cellular compartment
annotation for most of these 167 proteins is Membrane related (see
Figure S2; see Methods for more details). This supports their
association with membranes, possibly by farnesylation (albeit this
localization annotation might have been inferred from sequence
similarity). Furthermore, peptide library studies have demonstrat-
ed FTase-catalyzed farnesylation (under STO or MTO conditions)
of 50 of these Cxxx motifs (representing 66 human proteins) [17].
Finally, analysis of the putative target proteins with the PrePS
server predicts that most of them (90/167) are indeed FTase
targets, while the other 77 are not predicted to be farnesylated (see
Figure S3). To further characterize the latter, we proceeded with
in vitro experimental validation of selected sequences.
Figure 3. Energy distribution of all possible Cxxx sequences, as well as previously characterized peptides (STO, MTO and NON) [17].
The distributions of known single turnover (STO) and multiple turnover (MTO) peptide sequences overlap, and are both significantly shifted towards
low peptide energies, compared to peptide sequences that do not undergo farnesylation (NON). The thresholds obtained for the discrimination of
MTO/NON predict 1349 (17%; -1.1 threshold) and 2309 (29%; -0.4 threshold) of the possible tetramer peptide sequences to undergo farnesylation.
doi:10.1371/journal.pcbi.1002170.g003
Figure 4. A novel class of farnesylation targets. The sequence logos of different sets of Farnesylation targets are shown for A. 72 known
substrates (Dataset S1C); B. 77 MTO peptides from Dataset S1A; C. 1349 (out of 8000) sequences that pass the stringent threshold of -1.1 and are
predicted to undergo farnesylation – while position a2 of the motif is still prominently aliphatic (ILE/VAL/LEU/PHE), positions a1 and X are much more
versatile than expected; D. A subset of C with D/E at C-terminal position (238/1349) constitutes a novel substrate class for FTase (Logos created by
http://weblogo.berkeley.edu/).
doi:10.1371/journal.pcbi.1002170.g004
Identification of Novel FTase Targets
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Among these 77 proteins (containing 72 unique Cxxx motifs),
39 motifs had not yet been tested for in vitro farnesylation. The
second set chosen for experimental validation consisted of 16 top-
scoring peptides selected from these 39 motifs. Of the 16 tested
peptides, 9 and 4 peptides are farnesylated in vitro under MTO and
STO conditions, respectively, while only 3 were not farnesylated
by FTase (Table 1B). None of the 16 sequences in this second set
are predicted to serve as farnesylation targets by PrePS. Interest-
ingly, for 9 of these 16 sequences, PrePS predicts that the upstream
context of the motif is suitable for farnesylation. In these cases, the
PrePS negative prediction is based on the sequence of the Cxxx
motif. This suggests that improved characterization of the
contribution of the 4 C-terminal residues to farnesylation can
identify more farnesylation targets. Finally, for 8 of these 16
sequences, PrePS would predict farnesylation of the Cxxx motifs in
Table 1. Experimental evaluation of farnesylation of predicted peptide substrates: 26/29 (90%) of the predictions are indeed
farnesylated, including a novel class of farnesylation targets identified in this study.
PrePS prediction
Motif Derived from protein
c Full
d x-CVLS
e H-Ras-Cxxx
f Score
a Exp. Result
b
(A) Top-scoring peptides
CYLI - -3.96 MTO
CYLE - -3.82 STO
CYLV - -3.60 MTO
CFLV - -3.60 MTO
CLII ++ -3.51 MTO
CYVE - -3.43 MTO
CYIE - -3.40 MTO
CFIE - -3.34 STO
CLIV ++ -3.33 MTO
CYLL - -3.24 MTO
CYLD - -3.13 MTO
CWVI - -3.03 STO
CWLV - -3.01 MTO
(B) Top-scoring peptides that occur at C-termini of human proteins
CYVA Q9NTW7-3 - - + -2.88 MTO
CFLT Q2UVF0 -- - + -2.74 MTO
CAFI Q7Z2H8 -- + - -2.62 STO
CWLS A6QL63-3 - ++ -2.46 MTO
CCLS Q9NZM3-3 -- -- ++ -2.37 MTO
CTTE Q5T2R2-2 -- - - -2.14 STO
CHFH Q8TCU3-2 --- + -- -2.14 STO
CKLA Q9BPZ7-6 - - + -2.06 MTO
CWTC Q8NFG4-3 - ++ - -1.94 MTO
CSLI Q14CB8-5 - ++ +-1.90 MTO
CLFE Q9UHP7-3 -- + -- -1.77 None
CPFF Q8N693 --- - -- -1.69 STO
CGVG A6NHS1 - - + -1.65 MTO
CFDI Q8NEB5 -- ++ -- -1.59 None
CHCI Q99988 -- + - -1.56 None
CVCV O75391 - ++ -1.12 MTO
(A) Top-scoring peptides. (B) Top-scoring peptides that occur at C-termini of human proteins.
The novel class of farnesylation targets identified in this study that contains acidic C-terminal residues (see Figure 4D) are shown in bold.
aPeptide score for sequences as measured by the FlexPepBind protocol developed in this study.
bExperimental validation of farnesylation of predicted peptides in this study (see Methods).
cUniprot [24] identifier of human proteins containing putative farnesylation motif.
d-fPrePS predictions [7]:
dbased on 30 C-terminal residues of protein sequence;
ebased on 30 C-terminal residues of protein, with the last 4 residues replaced by the H-Ras canonical Cxxx motif (CVLS) (this indicates the amenability of the upstream
sequence to allow farnesylation of the C-terminus);
fbased on 30 C-terminal residues of known substrate H-Ras, with last 4 residues replaced by Cxxx motif (this indicates the amenability of the given Cxxx C-terminal
sequence to undergo farnesylation within the context of a known strong farnesylation target).
doi:10.1371/journal.pcbi.1002170.t001
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balance between the upstream signal and the C-terminal Cxxx
motif is therefore an interesting subject for future research.
Most of the proteins identified by this study as novel FTase
substrates have not been well characterized to date. Consequently,
in vivo experiments that evaluate the cellular localization and
prenylation status of these proteins, in conjunction with the in vitro
farnesylation demonstrated in this study, will advance their
functional characterization.
Discussion
We present here a simple and accurate structure-based scheme
for prediction of the sequence of FTase-binding peptides. We have
validated our protocol against several test sets, and predictions
were experimentally verified in vitro to reveal novel putative
FTase substrates and potential tight binders. This approach has
expanded our understanding of farnesylation, both within the
context of the reaction itself, as well as in the greater context of
cellular biology. Furthermore, this protocol presents an advance in
the computational prediction of binding specificity in general.
Insights into the mechanism of farnesylation from
structure-based predictions - Binding affinity vs.
reactivity
The protocol that we developed essentially estimates the binding
affinity of FTase for Cxxx peptides, using a training set of reactive
peptides, rather than predicting the farnesylation activity of these
sequences. This has several implications and limitations. Remark-
ably, the ability to discriminate peptides that undergo MTO
reaction from non-active peptides according to binding energy
suggests that the non-active peptides may bind weakly or not at all
to FTase (see Figure 3). This finding is supported by results from
an in vitro inhibition experiment in which none of the tested non-
active peptides inhibited FTase-catalyzed farnesylation of a known
substrate [17]. In turn, the members of the small class of
FlexPepBind false positive peptides may bind to FTase with high
affinity but still not be farnesylated. These false positive peptides
could therefore serve as FTase inhibitors and represent an in-
teresting set to characterize in future work.
Previous studies have shown that the sequence immediately
upstream of the conserved cysteine residue may also play a role in
substrate selectivity [16]. These sequences modulate peptide
affinity and reactivity with FTase, i.e. a high-affinity terminal
tetramer sequence does not necessarily ensure farnesylation of the
protein. For half of the proteins tested in the study, the PrePS [7]
program predicts favorable upstream sequences. This result
coupled with the high-affinity -Cxxx motif predicted by FlexPep-
Bind (see Results and Table 1B) increases the confidence that the
human proteins containing the said Cxxx motif could be
farnesylated in vivo. In turn, a favorable upstream sequence might
compensate for a weak C-terminal signal. Our future work will
therefore further characterize the balance between these two
signals in determining farnesylation.
STO peptide substrates
One puzzling aspect of FTase substrate recognition is the large
number of peptides that exhibit single turnover activity. The single
turnover rate constant, kfarn, reflects all of the rate constants up to
but not including the release of the farnesylated product
[4,26,27,28]. Therefore, the STO peptides bind to FTase and
are readily farnesylated, but the product dissociates very slowly so
multiple turnover activity is very slow. Consistent with this,
FlexPepBind achieves an AUC value of 0.776 in the discrimination
between STO and non-active peptides on the training set,
indicating that STO peptides have higher affinity for FTase than
the non-active peptides (see Figure 3). Our protocol thus identifies
STO peptides much better than sequence-based methods (see
Results and Hougland et al. [17]).
What then discriminates between MTO and STO peptides?
Hougland et al. postulated that the farnesylated STO peptides
might bind more tightly to FTase than farnesylated MTO
peptides, and as a consequence FPP-catalyzed product dissociation
is slow [17]. However, binding energy, as approximated by our
approach, seems to be a poor discriminator between MTO and
STO peptides (AUC value of 0.625 on the training set – Dataset
S1B). That is, estimation of the binding affinity of peptides in the
context of static conformations of the protein cannot explain the
difference in reactivity. Furthermore, application of this approach
to models of MTO and STO peptides at different stages of the
reaction sequence (pre-farnesylation, post-farnesylation with the
farnesyl group in the exit groove) was not able to account for this
difference as well. Hence, rather than binding affinity, a parameter
related to the dynamics of product dissociation might dictate turnover.
We therefore conclude that a dynamical approach, such as
molecular dynamics, will be required to explain the mechanism
that distinguishes STO from MTO peptides.
Are the proteins corresponding to MTO and STO
peptides FTase substrates in vivo?
Past in vitro peptide farnesylation experiments with FTase have
measured kcat/KM
peptide under MTO conditions and kfarn rate
constants under STO conditions [17]. The estimated reactivity of
MTO and STO peptides (see Methods) measured in this work falls
within the range of previously measured activity [17]. Therefore,
these peptides have comparable reactivity to other substrates,
including peptides that correspond to proteins that are farnesy-
lated in vivo.
Measured under MTO conditions, the kinetic parameter kcat/
KM
peptide is termed the specificity constant and best reflects the
reactivity of an enzyme in the presence of multiple substrates, as
observed in vivo [29]. In a cell, the reactivity of a protein substrate
with FTase depends on the value of kcat/KM
peptide as well as on the
concentration of the substrate within the cytosol. Although a
protein substrate with a higher value of kcat/KM
peptide is more likely
to be farnesylated in vivo, it is unclear what level of in vitro activity
corresponds to a true FTase substrate in vivo. Furthermore, in vivo
the optimal levels of farnesylation of a given substrate may vary
and a low fraction of modification may still be biologically
relevant. Additionally, a substrate must be localized to the proper
cellular locale in order for modification to occur and the C-
terminus of the protein must be structurally available. Peptide
library studies and this work have aided in determining potential
FTase substrates and have also identified already known
substrates, but more work is needed to characterize the reactivity
of these substrates in vivo.
As for the STO-only peptides, these substrates are readily
farnesylated but the product does not dissociate rapidly. One
possibility is that these proteins function as FTase inhibitors and
consequently play a regulatory role within the cell [17]. However,
both FPP and peptides have been implicated in catalyzing product
dissociation of farnesylated STO peptides [17,30,31] and therefore
it is possible that other cellular components could activate product
dissociation allowing rapid farnesylation of these proteins in vivo.
Therefore, competition or synergy among different FTase sub-
strates could play an important functional role for modification
and localization of proteins. Improved identification of STO
peptides using the structure-based FlexPepBind approach presented
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reaction. In addition, the overlap in substrate preference of FTase
and GGTase-I [3] indicates that modulation of the type of prenyl
modification (e.g. changes in relative enzyme availability or
magnesium concentration) might be functionally important as well.
Our future focus on structure-based characterization of GGTase-I
specificity will allow an improved investigation of this regulatory
feature, complementary to sequence-based studies [7,8].
Identification of new putative farnesylation targets
Scanning the human genome for putative FTase targets using
our structure-based approach revealed many putative, not yet
detected, farnesylated proteins. These new farnesylation substrates
may provide novel disease targets for farnesyltransferase inhibitors.
Moreover, the prediction that these proteins are farnesylated
might shed light on their function. As an example, the putative
proteins Q8NA34, A6NHS1, and P0C7P2 (UniProt identifiers
[24]) all contain C’ sequences strongly predicted to serve as
farnesylation targets suggesting that the proteins are membrane
localized. Additionally, our method also predicts FTase substrates
that have recently been identified from in vivo experiments. For
example, Kho et al. used a tagging-via-substrate proteomic
approach to discover novel farnesylation targets [32]. They found
a total of 18 farnesylated proteins: 13 are well known, and of the
remaining 5 our approach predicts 4 to be farnesylated, including
one hypothetical protein. Furthermore, it was recently found that
pathogens can hijack the host farnesylation machinery to their
own advantage, for example, anchoring effector proteins to the
membrane of Legionella-containing vacuoles [33,34,35]. Thus, in
addition to the identification of putative new farnesylation targets
in the human genome, FlexPepBind can be used to scan pathogen
genomes for farnesylation as well.
The biological relevance of putative novel targets
13/16 motifs derived from human proteins tested for in vitro
farnesylation indeed undergo the reaction. Will this also happen in
vivo? In the following we compile additional available details on
these targets that might help answer this question.
One way to assess the in vivo relevance of the observed in vitro
ability to undergo farnesylation of the C-terminus of a protein is to
look for homologous proteins that also undergo farnesylation. Such
information can easily be retrieved from PRENbase [8]. A search in
this database revealed that Kinesin-like protein KIF21B variant
(Q2UVF0; CFLT) maps to a cluster of 9 highly similar eukaryotic
sequences (E-val,e-20) that are all predicted to undergo farnesyla-
tion by PrePS. Similarly, Ankyrin repeat and BTB/POZ domain-
containing protein BTBD11 (A6QL63-3; CWLS) maps to a cluster
of 25 sequences of related proteins in PRENbase. Zinc finger
protein 64 homolog (Q9NTW7-3; CYVA) also contains a number
of conserved homologs in PRENbase, however in this specific
isoform the target cysteine is part of the Zinc-finger structural motif,
and therefore it might not readily be farnesylated.
Another interesting putative farnesylation target that we have
identified is the short isoform of Intersectin-2 protein (Q9NZM3-
3; CCLS). This protein is involved in clathrin-mediated endocy-
tosis [36,37], and farnesylation could be a mechanism for regulation
and localization to the membrane, similar to the prenylation of Rho
GTPases for endocytosis [38]. In particular, the long isoform of
intersectin-2 contains additional domains [39], including a PH
domain known to bind phosphoinositides [40], and a C2 domain
known to be involved in Ca-dependent and independent binding of
phospholipids [41]. Consequently, in the short isoform that lacks
these domains, farnesylation might indeed be used as an alternative
way to achieve membrane proximity and attachment. While the
localization of some Rho GAP proteins (e.g. p190 [42]) is regulated
by phosphorylation, the short isoform of Rho GTPase-activating
protein (GAP) 19 (Q14CB8-5; CSLI) exposes a new C’ motif that
may targetitto the membrane(while keepingthe Rho GAPdomain
intact). The same goes for MAPKAP1 isoform 6 (Q9BPZ7-6;
CKLA), a subunit of mTORC2. While the full length protein was
shown to contain a functional PH and Ras binding domains [43],
the truncated isoform reveals a C’ putative farnesylation motif
instead. Thus, for all but three MTO sequences we could gather
additional information that supports actual in vivo farnesylation. We
furtherdiscussalternativesplicingasaregulatorymechanismbelow.
Four motifs were found to undergo in vitro farnesylation under
STO conditions. The Homeobox protein ESX1 (Q8N693; CPFF)
is cleaved into an N’ and C’ domain; while the N’ enters the
nucleus, the C’ domain is localized to the cytoplasm where it
inhibits cyclin degradation[44]. A search for homologues in
PRENbase produced a cluster with 2 sequences predicted to
undergo farnesylation by PrePS. While the latter could support
actual farnesylation of this protein, in this case this modification
would serve for purposes other than membrane association, such
as the interaction with new partners [5]. Isoform 2 of the integral
membrane protein solute carrier family 7 member 13 (Q8TCU3-
2; CHFH) is missing an intracellular domain, and therefore places
its C’ in proximity to the membrane. Here farnesylation could play
a role in targeting this transmembrane protein to a specific
membrane compartment [45], resulting in different membrane
distributions for alternative spliced isoforms. Decaprenyl-diphos-
phate synthase subunit 1 isoform (Q5T2R2-2; CTTE) is a nuclear
encoded mitochondrial protein. If indeed farnesylated, this would
be a first example where an isoform of a mitochondrial protein is
farnesylated in the cytosol. Finally, the proton-coupled amino acid
transporter 1 (Q7Z2H8; CAFI) is likely not a farnesylation target,
since mutation of the target cysteine to alanine did not affect
its function [46]. As discussed above, the biological role of
farnesylation under STO conditions is not yet clear; furthermore,
if these proteins are farnesylated in vivo, the function is likely more
complex than localization to the membrane.
For the three motifs that were not farnesylated under in vitro
conditions, additional information about the cognate proteins
indeed suggests that the C-terminal cysteines are likely not
farnesylated in vivo. The target cysteines of Growth/differentiation
factor 15 (Q99988; CHCI) and the extracellular C-type lectin
domain family 2 member D isoform (Q9UHP7-3; CLFE) are part
of a conserved disulfide bridge and therefore most likely not
farnesylated in vivo.
In this study, we chose peptide motifs for in vitro experimental
characterization based on their predicted ability to bind FTase
and their novelty (i.e. not predicted by PrePS, and not yet
experimentally tested). While our post-hoc literature analysis
reinforces some of the predictions, other targets will apparently
undergo farnesylation only in vitro. The latter represent an
interesting set of proteins that allow the investigation of additional
factors that regulate the actual farnesylation in vivo, and that
therefore distinguish between the ability of a protein to undergo
farnesylation in vitro and in vivo. In any case, future in vivo validation
is required for all putative targets to unequivocally define their
functional importance in the cell.
Alternative splicing as regulator of farnesylation
Approximately half of the proteins strongly predicted by
FlexPepBind to undergo farnesylation (86/167) appear in
alternative splicing isoforms (according to Swissprot [24]; the
actual number of isoforms is expected to be higher, as more
experimental data accumulate from large scale sequencing efforts).
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in some of the isoforms. This may present a second layer of
regulation for the localization of such proteins, in which a
protein can reside in different cellular compartments as a
function of the isoform expressed at a given time or a given tissue
and therefore perform different functions. This form of
regulation may be a consequence of the irreversible nature of
farnesylation. On the other hand, farnesylation can be
maintained despite alternative splicing. For example, in Rab28
the two reported isoforms (hRab28S, hRab28L) differ only by a
95-bp insertion within the coding region [47]. This insertion
generates two alternative sequences in the 30 C-terminal amino
acids, which strikingly both contain a high-affinity farnesylation
motif (CSVQ – L isoform, CAVQ – S isoform) at the C-
terminus. This is similar to the case of KRas that also expresses
as two splice variants with strong farnesylation motifs (CIIM - 2A
isoform, CVIM - 2B isoform) and different upstream sequences.
In this case one upstream sequence harbors an additional
palmitoylation site, and may thus lead to different distribution in
the membrane [48].
Computational approaches for the prediction of binding
specificity – challenges and successes
FlexPepBind is a framework for designing peptides that bind to
a given protein, as well as for the prediction of peptide binding
specificity. It is based on our previously developed modeling
protocol FlexPepDock for peptide-protein structures [20]. Inclu-
sion of constraints derived from known structures with bound
peptides allows for the definition of backbone flexibility that is
appropriate for the specific system of interest, and optimization of
the energy function is based on a given set of binding and non-
binding peptides.
How much conformational freedom should be given to the
peptide in order to sample the correct conformation, without
introducing too much noise? What is the best score for dis-
crimination of active and non-active peptides? While Grigoryan et
al. were able to design peptides that bind to specific members of
the bZip family [49], Goldschmidt et al. identified fibril-forming
peptides on a large scale [50], and Kota et al. defined a binding
motif for type I HSP40 peptide substrates [51] using fixed
backbone conformations, the incorporation of backbone confor-
mational flexibility has generally improved computer-aided design
of functional protein interactions, as well as structure-based
prediction of peptide-protein and protein-protein interaction
specificity [52]. In particular, a range of backbone conformations
created by the backrub method [53] improved computational
sequence recovery of experimental phage display results on human
growth hormone [54], and variation along normal modes allowed
improved optimization of binding between the anti-apoptotic
protein BCL-xl and BH3 helical ligands [55]. Modeling of the
structure of HIV protease – peptide targets using a flexible docking
protocol allowed the distinction between peptides that are cleaved
from those that are not, opening new avenues towards the design
of HIV protease inhibitors [56].
In our modeling study of FTase binding peptides, side-chain
repacking alone that restricts sampling to a discrete rotameric
representation results in a low AUC value of 0.606 over the
training set. Simple minimization that allows for very subtle
backbone, side chain, and rigid-body adjustments relieves clashes
that cannot be resolved with a simple rotameric side-chain search,
and indeed improves performance significantly (AUC=0.875).
Much more extensive sampling with Rosetta FlexPepDock [20]
produces even better AUC values (up to 0.94). Therefore, the
more we sample, the better we perform. On the other hand,
restricted sampling can alsoimproveperformance:theincorporation
of conserved structural constraints into the simulations, as well
as the inclusion of the FPP farnesyl analog, significantly
improves the identification of farnesylation targets. The
performance of different sampling and scoring schemes is
summarized in Table S1.
Incorporation of additional FTase backbone conformations
from additional FTase-substrate complex structures could enhance
the predictions. To examine this, we evaluated the FlexPepBind
protocol with two additional backbone templates, and assessed for
each the performance on the training set. Using PDBs 1tn7 [9]
and 2h6f [57], we achieve comparable and slightly worse AUC
values of 0.85 and 0.75, respectively. Combining the scores based
on 1tn6 and 1tn7 gave a marginally better performance
(AUC=0.88) and could indeed represent an avenue for future
improvement of the protocol.
In addition to sampling, calibration of the energy function can
also improve the prediction of binding peptides. In a study on
PDZ-peptide interactions, Kaufmann et al. optimized the Rosetta
energy function on 28 peptide interactions with PDZ domain 3 of
PSD-95 for binding prediction. The resulting interface energy
using an increased contribution of the hydrogen bond term
produces a ROC plot with an AUC value of 0.78 on a general set
of 144 peptide-PDZ interactions [58].
In our study we find that scoring with the Rosetta energy
provided by the peptide provides the best results for the
discrimination of active and non-active peptides. This energy
includes the internal peptide energy as well as the interface energy,
minus a reference energy term that had been previously introduced
to optimize sequence recovery in the design of globular proteins
[46]. De-facto, removal of this term favors (in decreasing order)
C,W,F,H,Y,V,I,A,P and disfavors R,Q,N,E,D,K,S,M,T,G,L. Con-
sequently, without this term, hydrophobic residues will be favored,
and performance on the training set improved (probably due to the
significant proportion of hydrophobic residues in this set, see
Figure 4B). Inferior results are obtained using the Rosetta energy
score provided by the interface, as well as the total protein structure.
In addition, we would like to note that when using FlexPepDock for
sampling, averaging the scores of the best 10 models always gives
better results than using merely the top-scoring model (see Table S1
for the performance of different scoring functions).
While the FlexPepDock based protocol gives better results, it is
computationally expensive, however, and would impede large-
scale characterization (even though it may be the method of choice
to make specific decisions once a threshold has been determined
from the training set). We found that simple minimization worked
well for FTase specificity prediction (and is about 500 times faster
than the full FlexPepDock-based protocol). This is due to the
restricted nature of the binding - three very strong limitations
constrain the peptide backbone orientation. Other systems will
probably benefit from increased modeling of backbone flexibility.
In summary, proper calibration of the energy function together
with conformational sampling provides efficient structure-based
characterization of peptide-protein interactions. It has been
estimated that up to 40% of the cellular protein-protein interaction
network is mediated by peptide-protein interactions [59]. FlexPep-
Bind is generic in the sense that very little prior knowledge is needed
inorderto predictthe specificityprofile fora certainpeptide-protein
interaction. Given a structural template and a small set of known
examples, prediction can be made to identify additional putative
targets. We therefore anticipate that this approach can be expanded
to a large scale by adapting it to additional peptide-protein
interaction motifs in the cellular peptide-protein interaction
network.
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Detailed description of the protocol
Template structure. The complex of human FTase with
Rab2a C’ peptide was selected as template (PDB: 1tn6 [9]),
keeping only the four C’ residues of the peptide (CNIQ) and a co-
crystallized farnesyl analog ([(3,7,11-trimethyl-dodeca-2,6,10-
trienyloxycarbamoyl)-methyl]-phosphonic acid) in place. We also
evaluated the use of additional templates, such as 1tn7 [9] and
2h6f [57] (see Discussion).
Threading and repacking. Different terminal sequences
were threaded onto the peptide backbone and their side chains
were packed to find the optimal rotameric configuration (FTase
side chains were not allowed to move at this time). Extra rotamers
were used both for x1 and x2 angles during the rotameric search.
Extended FlexPepDock protocol. The prediction protocol
using Rosetta FlexPepDock [20] included the creation of 100
models for each of the sequences. Models were scored using the
scoring scheme described below, and for each sequence the top-
scoring model was chosen as representative.
Simple minimization protocol. Instead of FlexPepDock,
this simpler protocol applies only minimization over all of the
peptide’s degrees of freedom (i.e. all w/y/v angles, all of the side-
chains x angles, as well as the rigid-body orientation of the
peptide), the FTase interface side chains (Cb within 8A ˚ of the
peptide) and the FPP dihedral angles, using the Davidon-Fletcher-
Powell (DFP) minimization algorithm with an absolute tolerance
of 0.0001, as implemented in the Rosetta modeling suite [21].
Modelingwithconstraints. Both in the extended FlexPepDock,
as well as in the simple minimization protocols, simulations were
performed under three constraints that ensure the conservation of
observed characteristic structural features in the binding site (Figure 1).
The cysteine sulfur atom was forced to stay in its position (the Zn
2+ ion
was not included in the modeling, instead distance constraints to the
coordinating residues of FTase were used), and the two structurally
conserved hydrogen bonds were enforced as well (i.e. the hydrogen
bonds between C’ carboxylate - FTase Q167a and between
a2 backbone carbonyl oxygen - FTase R202b ˜Constraints were
implemented as harmonic distance functions with a standard
deviation of 60.1A ˚ of the original measured lengths. Constraints
with a larger standard deviation (60.25 A ˚) performed slightly better
(see Table S1).
Scoring. The chosen score for discrimination between MTO
sequences and non-active sequences consists of the sum of the
energy contribution of the 4 peptide residues (as calculated by the
Rosetta score12 energy function [22]), but excluding a constant
reference energy term (Eref) which is fixed per amino acid type and
was originally introduced to bias for native protein sequences
during fixed backbone sequence design [60].
The scoring schemes that were evaluated in this study include:
(1) Total score - the regular Rosetta score12 for the entire complex;
(2) Interface score - the score of the complex less the scores of the
peptide and receptor when pulled apart. This score accounts only
for interactions across the interface; (3) Peptide score - the sum of the
energy contribution of the 4 peptide residues; (4) Peptide score no
Ref.: same as Peptide score excluding a constant reference energy
term (Eref) which is fixed per amino acid type and was originally
introduced to bias for native protein sequences, and (5) iBSA:
Buried surface area of the interface. Table S1 summarizes the
performance of these different scoring schemes on the training set.
Genome scan
Human SwissProt [24] was downloaded from IPI [61] (newest
version available as of 19.01.10), and was scanned for sequences
containing a Cxxx regular motif as the last 4 residues in the
protein sequence.
GO enrichment analysis
Gene Ontology [25] terms were associated with each of the 167
identified candidates for farnesylation (see Results). Enrichment
for different cellular compartments, evaluated using DAVID [62],
extracted a subset of 93 proteins that are enriched with 18 GO
cellular compartment terms, most of them related to the
membrane (see Figure S2).
PrePS
We used the PrePS web-server [7] to obtain sequence-based
predictions on our set of 167 selected proteins. For each protein
suggested by our protocol to undergo farnesylation, we calculated
its prenylation ability using 30 C-terminal residues as input to the
server.
Experimental procedures
Farnesylation screens were performed using radioactivity assays.
Different conditions were used to assess the ability of Cxxx
sequences to undergo farnesylation under multiple turnover
(MTO) and single turnover (STO) conditions, as detailed below.
Peptides that do not undergo farnesylation under either of these
conditions were defined as NON (see Hougland et al. [17] for more
details).
Steady-state turnover (multiple turnover conditions). 3 mM
dansylated-peptide (dns-TKCxxx) was incubated with 1 mM
3H-
farnesyldiphosphate and 25 nM rat FTase in 50 mM HEPPSO,
pH 7.8, 5 mM TCEP, 5 mM MgCl2 at 25uC for two hours. The
reaction was quenched with 80:20 isopropanol:acetic acid and run on a
silica TLC plate (8:1:1 isopropanol:ammonium hydroxide: water). The
TLC plates were visualized by autoradiography. Peptides that were
observed to be at least 10–20% reacted, as compared to dns-GCVLS,
were considered MTO substrates. Using the assumptions that
[peptide] , KM and that [FPP] is saturating, the lower limit of this
assay is approximately 200–400 M
21s
21, similar to previous work [17].
Single turnover. Single turnover assays were carried out the
same way as the MTO assays, except that 1 mM FTase, 0.8 mM
3H-FPP, and 3 mM dns-TKCxxx peptide were incubated for one
hour before the reaction was quenched. Peptides were considered
a STO substrate if at least 10 - 20% of the
3H-FPP reacted with
the peptide after one hour. The range of reactivity of the STO
substrates measured in this study is similar to that observed in
other studies [17].
Supporting Information
Figure S1 Structural basis of the novel CxxE binding
motif. Models of CYLE (green) CYVE (cyan) CYIE (magenta)
CFIE (yellow) peptides bound to FTase (orange) are shown. The
models suggest that the negatively charged C’ Glutamate residue
of the peptide is stabilized by FTase His149 and forms hydrogen
bonds with Trp102 and Ser99. Additional potential interactions
with water molecules might exist, but are not modeled.
(PNG)
Figure S2 According to GO cellular compartment anno-
tation, most of our predicted substrates in the human
genome are associated with the membrane, suggesting
that they indeed might be farnesylation targets.AG O
cellular compartment enrichment analysis conducted with DAVID
[62] discovered 18 GO cellular compartment terms enriched in a
subset of 93/167 of the predicted substrate proteins. Red columns
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counts for the term in the dataset.
(PNG)
Figure S3 FlexPepBindidentifies 77 novel putativetargets
undetected by PrePS. T h ep l o ts h o w st h ed i s t r i b u t i o no fP r e P S
predictions on the set of 167 protein sequences that were predicted to
undergo farnesylation by FlexPepBind. Almost half of these
sequences were not detected by PrePS (in red). The number of +
and – symbols indicates the confidence of PrePS in its prediction of a
substrate and non-substrate, respectively.
(PNG)
Dataset S1 The different peptide sequences datasets
used for training and testing in this study. A Training
set. 77 MTO and 51 NON peptide sequences. B Test set 1.
Secondary synthetic library: 29 MTO and 15 NON peptide
sequences. CT e s ts e t2 .72 Known FTase substrate
sequences (from naturally occurring proteins) DT e s ts e t3 .
Ca1a2L library containing 24 binding and 17 non-binding
peptides.
(XLS)
Table S1 Optimization of the FlexPepBind protocol on
the training set: performance of different schemes. In
this table we report the performance of the FlexPepBind protocol
over the training set using different sampling and scoring schemes.
(DOCX)
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